Table 1.

Patient demographic data, past history and individual renal and oncological outcomes

Kidney Biopsy	Age range (yr)	Gender	BMI (kg/m2)	Comorbidities	Medications prior to renal IrAE	Immunotherapy regimen	Renal function 3m	Oncological outcome
Yes	40-49	Male	25.1	Nil	Nil	Ipilimumab + Nivolimumab	CKD 2	CR
Yes	50-59	Male	25.6	HTN	Metoprolol 50mg twice daily, amdodipine 10mg daily	Ipilimumab + Nivolimumab	CKD 3a	CR
Yes	60-69	Male	26.2	Nil	Nil	Ipilimumab + Nivolimumab	CKD 2	PR
Yes	70-79	Male	29.2	HTN, BPH, nephrolithiasis, acquired hypopituitarism	Thyroxine 100mcg daily, Prednisolone 10mg daily.	Ipilimumab + Nivolimumab	CKD 3a	PR
Yes	70-79	Male	27.5	HTN, dyslipidaemia, IHD, BPH, GORD	Quinapril 5mg daily, rosuvastatin 20mg daily, allopurinol 200mg daily, rabeprazole 20mg daily.	Pembrolizumab + Epacadostat	CKD 3a	PD
Yes	70-79	Male	24.6	HTN, IHD, DM, Diverticular disease.	Amitriptyline 50mg daily, telmisartan 40mg daily.	Ipilimumab + Nivolimumab	CKD 3a	PD
Yes	70-79	Male	29.2	IHD, BPH, HTN	Aspirin 100mg daily, clopidogrel 75mg daily, atorvastatin 20mg daily.	Ipilimumab + Nivolimumab	CKD 3b	PD
Yes	60-69	Female	41.2	HTN, GORD, rectal cancer.	Perindopril 2.5mg daily, rabeprazole 20mg daily.	Ipilimumab + Nivolimumab	CKD 3a	CR
Yes	70-79	Male	28.5	Acquired hypopituitarism	Hydrocortisone twice daily, thyroxine 100mg daily	Ipilimumab + Nivolimumab	CKD 4	CR
Yes	50-59	Male	26	Previous pulmonary embolus	Nil	Ipilimumab + Nivolimumab	CKD 5	CR
Yes	80-89	Male	23	Idiopathic cardiomyopathy. PMR.	Data not available	Pendrolizumab	CKD 3b	SD
Yes	30-39	Male	27	Nil	Nil	Ipilimumab + Nivolimumab	CKD 2	PD
No	40-49	Male	35.9	HTN, Obesity, Depression	Perindopril 5mg daily, venlafaxine 75mg daily	Ipilimumab + Nivolimumab	CKD 2	CR
No	70-79	Male	28.1	T2DM, HTN, IHD, dyslipidaemia, smoker, BPH	Quinapril 5mg daily, rosuvastatin 20mg daily, metformin 1000mg daily, gliclazide 60mg daily, dapaglifozin (unknown dose) daily.	Ipilimumab + Nivolimumab	CKD 3a	PD
No	70-79	Female	31.6	HTN, dyslipidaemia	Data not available	Ipilimumab + Nivolimumab	CKD 3a	PD
No	70-79	Male	33	T2DM, HTN, dyslipidaemia, IHD, PVD, BPH, haemochromatosis, EtOH excess	Aspirin 100mg daily, clopidogrel 75mg daily, perindopril 5mg daily, hydrochlorothiazide 12.5mg daily, amlodipine 10mg, atorvastatin 40mg daily.	Ipilimumab + Nivolimumab	CKD 3b	CR
No	50-59	Male	31.3	Nil	Data not available	Pendrolizumab	Full recovery	PR
No	60-69	Male	27.8	HTN, CVA, cardiomyopathy.	Bisoprolol 5mg daily	Ipilimumab + Nivolimumab	CKD 3a	PR
No	70-79	Male	24.9	HTN, Seizures,	Aspirin 100mg daily, irbesartan 150mg daily, alendronate, simvastatin 40mg daily, Omeprazole 20mg daily, monoxidine 200mcg daily.	Ipilimumab + Nivolimumab	CKD 3b	CR
No	60-69	Male	N/A	Nil	Nil	Ipilimumab + Nivolimumab	CKD 2	PR
No	70-79	Male	N/A	IHD, T2DM, dysllipidaemia.	Candesartan 32mg daily, aspirin 100mg daily, clopidogrel 75mg daily, simvastatin 40mg daily, propanolol 80mg daily, Ranitidine 150mg daily	Ipilimumab + Nivolimumab	CKD3b	CR
No	70-79	Male	27.5	Bladder Ca (sx), IHD, AF, DVT	Aspirin 100mg daily, nicorandil 10mg daily, rosuvastatin 20mg.	Pembrolizumab	CKD 3a	CR
No	80-89	Male	N/A	Bullous pemphigoid, DM, DVT, PVD, AF	Apixaban 2.5mg twice daily, metformin 1000mg daily, rosuvastatin 20mg daily, pantoprazole 40mg daily, gliclazide 60mg daily.	Nivolimumab	CKD 3b	PD

HTN – hypertension, IHD – Ischemic Heart Disease, PVD – peripheral vascular disease, BPH – Benign prostatic hypertrophy, GORD – Gastro Oesophageal Reflux Disease, PE – pulmonary embolus, CA – cancer, T2DM – Type 2 diabetes mellitus, EtOH – alcohol excess, CVA – stroke, AF – atrial fibrillation, DVT – deep venous thrombosis, CKD – chronic kidney disease, CR – Complete remission. PR – partial remission. SD – Stable disease. PD = progressive disease